LIVING DONOR LIVER DONATION IN THE ONCOLOGICAL FIELD: WHAT’S NEW

Le résumé fourni par la source

Liver transplantation is emerging as a promising strategy to treat several malignancies, in selected patients. However, expanding the indication for LT to oncologic indication exacerbates the persisting shortage of grafts. Living donor liver transplantation (LDLT) appears as a useful solution to enlarge the donor pool to meet this need. This review aims to comprehensively explore the current indications for LDLT in the context of hepatic malignancies, emphasizing reported outcomes and presenting future perspectives. A particular attention will be devoted to ethical considerations. The review will focus on the role of LDLT for hepatocellular carcinoma (HCC), for intrahepatic and perihilar cholangiocarcinoma (iCCA and pCCA), and for colo-rectal liver metastases (CRLM). Lastly, we will present new techniques of living transplantation using small left lateral grafts, namely RAPID Resection And Partial Liver segment II-III transplantation with Delayed total hepatectomy) and dual-graft transplantation (DG-LDLT).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.